Startups
We use AI to discover better medicines faster -- then our team of industry veterans rapidly takes those candidates into clinical trials. AI Drug Development is the future of pharmaceutical drug discovery. X-37’s world-class development team includes CEOs, Chief Medical Officers, and Executives who have successfully led the development and regulatory approval of a wide range of human therapeutics.
Overview
Location
United States, California, South San Francisco
Employees
11-50
Total raised
$14.5M
Founded date
2018
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 21, 2021 | MK Venture Capital | mk-vc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 19, 2019 | AI-Enabled Drug Discovery Company X-37 Announces $14.5 Million In Funding | Enabled drug discovery company X-37 announced it closed $14.5 million in Series A funding led by DCVC Bio X-37 — an AI-enabled drug discovery company — announced it has closed $14.5 million in Series A funding. This round of funding was led... |
| Nov 15, 2019 | Atomwise's X-37 spinout gets $14.5 million to launch AI discovery efforts | The folks behind Atomwise’s spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in ... |
| Nov 15, 2019 | X-37 Announces $14.5M Series A | SOUTH SAN FRANCISCO, CA, Artificial intelligence-enabled drug discovery company, announced today that it has closed a $14.5 million Series A financing. >> Click here for more funding data on X-37 >> To export X-37 funding da... |
| Nov 14, 2019 | New Atomwise offshoot X-37 raises $14.5M to shepherd AI-designed drugs | Molecule prospector Atomwise co-founded a drug research company alongside Velocity Pharmaceutical Development designed to shepherd its artificial intelligence-derived candidates through preclinical testing and into potential takeout deals w... |
| Nov 14, 2019 | New Atomwise offshoot X-37 raises $14.5M to shepherd AI-designed drugs | Molecule prospector Atomwise co-founded a drug research company alongside Velocity Pharmaceutical Development designed to shepherd its artificial intelligence-derived candidates through preclinical testing and into potential takeout deals w... |
| Nov 14, 2019 | X-37 Raises $14.5M in Series A Funding | X-37, a South San Francisco, CA-based artificial intelligence-enabled drug discovery company, closed a $14.5m Series A financing. The round was led by DCVC Bio with participation from Alpha Intelligence Capital and Hemi Ventures. Following ... |
Reviews 0
FAQ about X-37
When was X-37 founded?
X-37 was founded in 2018.
How much funding has X-37 raised?
X-37 has raised $14.5M in total across 1 funding round.
Who has invested in X-37?
Parsers VC lists 2 investors of X-37, among them MK Venture Capital.
What has the press written about X-37?
Parsers VC has collected 7 articles mentioning X-37, among them “AI-Enabled Drug Discovery Company X-37 Announces $14.5 Million In Funding” (Nov 19, 2019) and “Atomwise's X-37 spinout gets $14.5 million to launch AI discovery efforts” (Nov 15, 2019).
Is X-37 still active?
Yes, X-37 is active; its latest activity on Parsers VC dates from Apr 21, 2021.